Mesenchymal stem cells (MSCs) have an inhibitory effect on tumor proliferation, but the precise mechanisms are not fully understood. Here, we identified DKK-1 (dickkopf-1), secreted by MSCs and acting as a negative regulator of WNT signaling pathway, to be one of the molecules responsible for the inhibitory effect. When DKK-1 was neutralized by anti-DKK-1 antibodies, or when the expression of DKK-1 was downregulated by RNA interference (RNAi), the inhibitory effects of MSCs on K562 cell proliferation were attenuated. We also provide evidence that the expression of DKK-1 by MSCs is regulated by NANOG, a transcriptional factor ubiquitously expressed in some stem cells. Using the Cellmax artificial capillary modules that eliminate the immunosuppressive properties of MSCs, we further showed that MSCs were able to inhibit proliferation of K562 cells in a humoral microenvironment. Meanwhile, we recapture this effect of MSCs on primary leukemic hematopoietic progenitors from patients. MSCs probably have a general inhibitory effect on their neighboring cells, including malignant cells, en route to achieving tissue homeostasis.
Introduction
Owing to their capacity to differentiate into multiple cell types, mesenchymal stem cells (MSCs) have received much attention for their diverse applications. They can be used as seeding cells for tissue engineering and as delivery systems in gene therapy. 1, 2 They also exhibit a profound immunosuppressive activity that can be exploited to prevent and treat graft-versus-host disease in bone marrow transplantation. 3 As the precursors of matrix cells, MSCs secrete various cytokines and chemokines that suppress the proliferation of lymphocytes by arresting them at G0/G1 phase. [4] [5] [6] [7] It is noted that TGF-b (transforming growth factor-b) was shown to be one of the factors mediating T-cell suppression. 8, 9 Ohlsson et al. 10 showed that the outgrowth of the rat colon carcinoma could be inhibited by mesenchymal progenitor cell line MPC1cE. MSCs also caused the transient arrest of tumor cells in the G1 phase of the cell cycle. 10, 11 The arrest of tumor cells in the G1 phase was accompanied by increased expression of CyclinA, CyclinE, CyclinD2 and p27KIP1. Recently, Khakoo et al. 12 further
showed that MSCs exert potent antitumorigenic effects in a model of Kaposi's sarcoma. The in vivo tumor-suppressing effect of MSCs correlates with their ability to inhibit the AKT activity in target cells. However, the inhibition of the in vitro activation of the AKT protein kinase by MSCs did not apply to all tumor and primary cell lines. This indicates that other pathways are involved in MSC-mediated inhibition of tumor growth.
The canonical WNT/b-Catenin pathway regulates cell fate during the development of vertebrates and invertebrates. In addition to its pivotal roles in developmental regulation, abundant evidence implicates its involvement in tumorigenesis.
13,14 DKK-1 (dickkopf-1), a negative WNT signal regulator, 15, 16 is potentially involved in the antiproliferation effect of MSCs. 17 In this study, we show that MSCs inhibit the proliferation of tumor cells by secreting DKK-1, which in turn suppresses the WNT signaling pathway, and this inhibition is dependent on NANOG.
Materials and methods

Tumor cell culture
The human carcinoma cell lines K562, HL60 and MCF-7 were maintained in RPMI 1640 medium (Gibco Life Technologies, Paisley, UK) supplemented with 10% fetal calf serum (Gibco) in humidified 5% CO 2 /95% atmosphere at 37 1C.
Isolation and culture of MSCs from adipose tissue
After informed consent, the isolation and culture of MSCs from human adipose tissue were performed as reported earlier. 18 Before their use in the experiments, MSCs were evaluated for the expression of Flk1, CD29, CD44, CD105, HLA-ABC, CD34, CD45 and HLA-DR.
Cell proliferation and cell cycle of tumor cells cocultured with MSCs
In mitogen proliferative assays, irradiated MSCs (30 Gy) were cocultured with the tumor cell lines at a ratio of 1:10 (MSCs to tumor cells) as reported earlier. 11 Control wells contained only tumor cells. Cultures were pulsed with 1 mCi/well-TdR (Shanghai Nucleus Research Institute, China) on day 2 and harvested 18 h later with a Tomtec automated harvester (Wallac Inc., Turku, Finland). Thymidine uptake was quantified in liquid scintillation and luminescence counter (Wallac MicroBeta TriLux, Waltham, MA, USA).
K562 cells were cultured alone or cocultured with MSCs for 2 days, then harvested and quantified. One million K562 cells were fixed with 70% cold ethanol at 4 1C for 30 min, washed with phosphate-buffered saline twice, and stained with 50 mg/ml propidium iodide (Sigma, St Louis, MO, USA) at room temperature for 5 min. Data were analyzed with ModFIT software. Neutralizing antibodies against DKK-1 (R&D system) and TGF-b (R&D system, Minneapolis, MN, USA) were added to K562 at a density of 1 mg/ml (see Supplementary Figure 1 ) and the transwell system. Transwell chambers with a 3.0-mm pore size membrane (Corning Costar, Cambridge, MA, USA) were used to physically separate the K562 cells from MSCs.
Vector construction
MSCV-neo-pSilencer, a RNA interference vector based on MSCV-neo (Clontech, Mountain View, CA, USA), was modified by inserting a siRNA (small interfering RNA) expression cassette into the multiple cloning sites and deleting the 3 0 LTR enhancer region (U3). MSCV-neo-siMock (RNA interference (RNAi) nonsilencing control), MSCV-neo-siDKK1 (targeting DKK-1) and MSCV-neo-siNANOG (targeting NANOG), respectively, were constructed by inserting short hairpin RNA templates into the siRNA expression cassette. The short hairpin RNA templates specific to their target genes (DKK-1: GenBank accession number NM_012242, position 366-386, 5
0 -GGAATAAGTAC CAGACCATTG-3 0 ; NANOG: accession no. NM_024865, position 808-828, 5
0 -AACCAGACCTGGAACAATTCA-3 0 ; MOCK: 5 0 -TTCTCCGAACGTGTCACGT-3 0 ) was designed, synthesized and annealed as reported earlier. 19 To construct NANOG overexpression vector, a full-length human NANOG CDS was obtained by reverse transcription (RT)-PCR from MSC cDNA and cloned into retroviral expression vector pMSCV-neo (Clontech).
Retrovirus preparation and transduction
Retroviral production and transduction of MSCs were essentially carried out as described. 20 MSCs were selected in culture media containing G418 (400 mg/ml, Sigma) 24 h after transduction. MSCs with different genes knockeddown were named as MSC-siMock, MSC-siDKK1 and MSC-siNANOG, respectively.
RNA extraction, reverse transcription and quantitative PCR
Total RNAs were extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA), and genomic DNA from all samples was removed using the RNA-free DNase digestion kit (Takara, Kyoto, Japan) according to the manufacturer's protocol. One microgram of total RNA was reverse transcribed using the Reverse Transcriptase M-MLV (Takara). PCRs were carried out using Taq DNA polymerase (Takara) and the primer sequences used to identify gene expression are listed in Table 1 
Western blot
Cells were lysed in ice-cold lysis buffer (1% Triton X-100, 20 mmol/l Tris-HCl (pH 8.0), 137 mmol/l NaCl, 10% glycerol (v/ v), 2 mmol/l EDTA, 1 mmol/l phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 50 mg/ml trypsin inhibitor, 1 mmol/l sodium orthovanadate) for 15 min. Cell lysates were then clarified by centrifugation and aliquots of each were removed for protein determination by the BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Standard western blotting procedures were used with the polyclonal anti-NANOG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), polyclonal anti-DKK1 (Santa Cruz), polyclonal anti-b-catenin (Cell signaling, Danvers, MA, USA) or polyclonal anti-GAPDH antibody (Santa Cruz) and anti-mouse/anti-rabbit/anti-goat horseradish peroxidase-conjugated secondary antibodies (Zhongshan, Beijing, China). Antibody/antigen complexes were detected using ECL reagent (Millipore, Billerica, MA, USA).
Chromatin immunoprecipitation assay
We performed chromatin immunoprecipitation (ChIP) as described earlier. 21 Antibodies used in this experiment were anti-Nanog goat polyclonal antibody (Santa Cruz) and normal goat IgG (Santa Cruz). The DNA isolated from the complex was subject to PCR amplification using primers flanking the NANOG-binding site 22 in the DKK-1 gene promoter: 5 0 -GGAG GAGGGCAACTGAAGGAC-3 0 (forward) and 5 0 -CCTCTCCTTT ATGCCAATACTCGC-3 0 (reverse). The PCR products were run on a 2% agarose gel and stained with ethidium bromide.
Capillary assay
Six-to eight-week-old male nude mice (BALB/c-nu) were purchased from the Experimental Animal Institute of the Chinese Academy of Medical Sciences (Beijing, China), bred and maintained under defined flora conditions in individually Table 1 List of primers for real-time reverse transcription-PCR 
Proliferation assays for primary leukemic samples
Bone marrow (BM), collected according to the institutional guidelines, was obtained from six adult untreated leukemia patients (with chronic myeloid leukemia). All volunteers have signed the IFC informed consent. Diagnosis was established by BM aspirate smears, BM biopsy, cytogenetic analyses and peripheral blood count criteria according to the FrenchAmerican-British group.
The leukemic hematopoietic progenitors from BM were fractionated over the 1.077 g/ml Ficoll-Paque density gradient; the interface was collected and resuspended in RPMI 1640 medium (Gibco Life Technologies) supplemented with 10% fetal calf serum (Gibco). As the proliferation, differentiation and maintenance of the hematopoietic progenitors in vivo are dependent on the microenvironment produced by stromal cells, [23] [24] [25] the leukemic hematopoietic progenitors were cocultured with MSCs or HSF (human skin fibroblast) stromal cells (control) at a ratio of 5:1, respectively. After 48 h, the cell cycle of leukemic hematopoietic progenitors was detected by FACS. HSF cell line was maintained in Dulbecco's modified Eagle's medium with high glucose (Gibco Life Technologies) supplemented with 10% fetal calf serum (Gibco) in humidified 5% CO 2 /95% atmosphere at 37 1C.
Statistics
Statistical analysis was performed with the statistical SPSS 13.0. software. The two-tailed student's t-test was used to test the probability of significant differences between samples. Statistical significance was defined as Po0.05.
Results
MSCs inhibit the proliferation of tumor cells
Human MSCs in this research were obtained from lipoaspirates from several healthy young women undergoing selective suction-assisted lipectomy and were pooled for all experiments. The phenotype and karyotype of human MSCs were evaluated after three passages. They were positive for the expression of Flk1, CD29, CD44, CD105 and HLA-ABC, whereas negative for CD34, CD45 and HLA-DR. They have normal karyotypes (data not shown). These features are consistent with our previous findings. 18 Three tumor cell lines of different lineages were used to test the inhibitory effect of MSCs on their proliferation in vitro. Two tumor cell lines are of hematopoietic origin (K562, HL60) and the other is a human breast adenocarcinoma cell line (MCF7). When tumor cells were cocultured with MSCs at a 10:1 ratio in a 24-well plate, the cell proliferation rate decreased significantly when compared with the control group: 77% decrease for K562, 80% for HL60 and 56% for MCF7, respectively (Po0.05) (Figure 1a) . We used K562 cells in further experiments to explore the mechanisms underlying MSC-mediated tumor cell suppression.
MSCs inhibit tumor cell proliferation through secreting soluble factors
The cell cycle status of K562 cells was examined 48 h after cells were cocultured with MSCs. As shown in Figure 1b , the proportion of cells in G0/G1 phase was significantly higher in Group 1 (K562 þ MSCs), 62.07 ± 5.8%, than in control (K562 alone), 45.23±6.9%, suggesting that more K562 cells are arrested at the G0/G1 phase in the presence of MSCs. To investigate whether MSCs inhibit K562 proliferation through secreting soluble factors, a transwell assay that physically separates MSCs from K562 in coculture was performed in parallel ( Figure 1b, Group 2) . The statistically significant difference was observed between Group 2 (63.65±8.43%) and the control (Figure 1b) , though no significant difference was 
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DKK-1 as an inhibitory factor on tumor cell proliferation
Earlier studies showed that MSCs can secrete DKK-1 and TGF-b, the key extracellular factors involved in proliferation-related cell signaling pathways. 8, 9 RT-PCR showed that DKK-1 and TGF-b were not expressed in K562 cells, and that the cell cycle status of K562 cells was not influenced when neutralization antibodies against either DKK-1 or TGF-b were added to the media in which K562 cells were cultured alone, thus excluding the possibility of self-regulation of K562 by autocrine DKK-1 and TGF-b (data not shown). To test whether such soluble cytokines are involved in MSCs' inhibition of K562 proliferation, we added neutralizing antibody against DKK-1 or TGF-b to the MSCs and K562 coculture, respectively. Although the addition of neutralizing antibody of TGF-b failed to reverse the change of cell cycle status caused by MSCs (Figure 1b, Group 4) , which was consistent with an earlier report, 11 the addition of neutralizing antibody of DKK-1 restored the proportion of K562 cells in G0/G1 phase to 49.22 ± 1.21%, a number similar to that of the control (Figure 1b, Group 3) . The above results suggest that DKK-1, but not TGF-b, plays an important role in suppressing K562 proliferation.
DKK-1 knockdown in MSCs led to a reduced inhibition of tumor cell proliferation
To further confirm that DKK-1 is a key factor in the inhibitory effect of MSCs on cell proliferation, we constructed a retrovirus-based RNAi vector that can transfect MSCs with high efficiency. MSCs were transiently infected with the retroviral supernatant containing siRNA specific to human DKK-1, and the DKK-1 knockdown was evaluated for each transfection. On average, DKK-1 was reduced by about 75%, as evaluated by real-time RT-PCR ( Figure 2a ) and by western blot (Figure 2b) .
We then evaluated the overall proliferation rate (Supplementary Figure 2 ) and cell cycle distribution of K562 cells in the siMock group and siDKK1 group (Figure 2c ). Similar to the results obtained with the DKK-1 antagonist assay, the proportion of K562 cells in G0/G1 phase was reduced in the siDKK-1 group when compared with the siMock group (52.09±3.36 vs 62.02 ± 4.36%, Po0.01). Residual DKK-1 in the siDKK-1-treated cells may account for a higher proportion in G0/G1 phase of cells in siDKK1 group than in the normal group (K562 cells alone). Meanwhile, we cannot exclude the possibility that other inhibitory factors might be also involved in the suppression of K562 proliferation.
DKK-1 affects tumor cell proliferation through canonical WNT signaling pathway
Activation of the canonical WNT pathway can lead to an accumulation of b-catenin, which in turn induces cell cycle progression through G1/S transition and promotes cell proliferation. 14 We examined the effects of DKK-1 on the accumulation of b-catenin by western blot and the expression profile of canonical G1/S checkpoint regulators such as c-MYC, CyclinD2, p21CIP1 and p27KIP1 by real-time RT-PCR in K562 cells. We confirmed that the accumulation of b-catenin was decreased when recombinant human DKK-1 protein was added into K562 cells culture (Supplementary Figure 3) . We also observed that the accumulation of b-catenin was increased when endogenous DKK-1 of MSCs was knocked down. Although the accumulation of b-catenin in the siMock group (K562 þ MSC-siMock) was decreased when compared with the Normal group (K562 cells alone), it was increased in the siDKK1 group (K562 þ MSC-siDKK1) to an intermediate level between the siMock group and Normal group (Figure 3a) . c-MYC and CyclinD2, positive regulators of cell cycle progression at G1 phase, are known as the target genes of the WNT signaling pathway. We found that their expression was decreased in the siMock group (K562 þ MSC-siMock), but was restored in the siDKK1 group (K562 þ MSC-siDKK1) to an intermediate level between the siMock group and Normal group (Figures 3b and c) . In addition, p21CIP1 and p27KIP1, negative regulators of cell cycle progression at G1 phase, were upregulated in the siMock group but downregulated in the siDKK1 group (Figures 3d  and e) . Taken together, the above results suggest that the DKK-1 secreted by MSCs inhibits cell proliferation by suppressing WNT signal activity. 
Expression of DKK-1 in MSCs are dependent on NANOG
NANOG is a transcriptional factor essential for the maintenanace of pluripotency and self-renewal of embryonic stem cells. 22, 26 We found that MSCs isolated from human adult adipose tissues can also express NANOG (Figures 4b and c) . To evaluate whether DKK-1 expression in MSC cells is regulated by NANOG, we performed ChIP assays and found that NANOG could bind directly to the promoter of DKK-1 (Figure 4a ). To determine whether expression of DKK-1 in MSCs is dependent on NANOG, we performed RNAi specific to NANOG in MSCs and evaluated the expression of DKK-1. On average, RNAi of NANOG reduced the levels of NANOG by about 80%, as evaluated by real-time RT-PCR ( Figure 4b ) and western blot ( Figure 4c ). As expected, the expression of DKK-1 was significantly downregulated with NANOG knockdown in MSCs (Figures 2a and 4c) . On the other hand, the expression of DKK-1 was not affected when NANOG was overexpressed using the retroviral gene transfer system in MSCs (data not shown).
We subsequently evaluated the overall proliferation rate (Supplementary Figure 2) and cell cycle distribution of K562 cells in the siMock group and siNANOG group. The result was similar to that obtained with the siDKK1 assay (Figure 5a ): the proportion of K562 cells in G0/G1 phase was significantly reduced in siNANOG group (46.32 ± 4.77%) compared with the siMock group (62.02±4.36%). Meanwhile, there was no obvious change in cell cycle distribution of K562 after coculturing with MSCs in which NANOG is overexpressed (data not shown). As expected, changes in expressions of b-catenin (Figure 5b ) and canonical G1/S checkpoint regulators such as c-MYC, CyclinD2, p21CIP1 and p27KIP1 were similar to those in siDKK1 experiments (Figures 5c-f) . Taken together, the results indicate that NANOG, a pivotal transcriptional factor for maintaining MSCs pluripotency, is also involved in the inhibitory effect of MSCs on tumor cell proliferation, and that this function is executed through the upregulation of DKK-1 expression.
MSCs inhibit tumor cell proliferation in a humoral microenvironment
To investigate the inhibitory effect of MSCs on K562 carcinoma cell proliferation in a humoral microenvironment and to avoid potential disturbance by immune system as well, we used the Cellmax artificial capillary device, embedded into the abdomen of nude mice. MSCs and K562 cells could grow together but are 
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Antiproliferative effect of MSCs Y Zhu et al confined inside the device. We found that the distributions of cell cycle of K562 cells in four independent groups were consistent with those observed in in vitro experiments ( Figure 6) . Again, the proportion of K562 cells in G0/G1 phase was significantly higher in the siMock group (K562 þ MSC-siMock) than in the Normal group (K562 alone), 60.93±8.57% vs 38.10 ± 4.05%, Po0.05. The inhibitory effect of MSCs was compromised when DKK-1 or NANOG was knocked down, 54.15 ± 3.87% in the siDKK1 group and 45.23 ± 4.1% in the siNANOG group. These results were consistent with those obtained in vitro.
MSCs can exert its tumor-suppressive function on leukemic cells from patients
To validate the tumor-suppressive function of MSCs on primary leukemic cells, we detected the cell cycle status of primary leukemic cells (that is, leukemic hematopoietic progenitors) isolated from different leukemia patients after coculture with MSCs or HSF stromal cells (control). Consistent with our earlier findings from the K562 cell line, the leukemic hematopoietic progenitors showed an attenuated proliferation activity after coculture with MSCs when compared with the corresponding control (Supplementary Figure 4A) . As expected, HSF stromal cells did not express NANOG and expressed DKK-1 weakly (Supplementary Figure 4B) , which lends support to our earlier investigation on the tumor-suppressive mechanism of MSCs.
Discussion
Although MSCs have been shown to inhibit the growth of highly proliferative cells, such as activated T lymphocytes and tumor cells by many researchers, the precise mechanisms are largely unknown. [4] [5] [6] [7] One recent study showed that MSCs were able to keep tumor cells arrested in G0/G1 phase. 11 We showed that MSCs from adipose can exert the same effect on tumor cells as can MSCs from BM, 11, 27 unpublished data. Thus adiposederived MSCs were used in this study for their easier availability. 28 Mesenchymal stem cells may inhibit tumor cell proliferation either through direct cell-cell interaction or by secreting various cytokines. An earlier report has shown that coculture of human MSCs with Kaposi's sarcoma cells inhibits activation of AKT within KS cells in a contact-dependent manner. 12 In our study, we showed that MSCs can inhibit K562 proliferation in a contact-independent manner and identified that the inhibitory effect of MSCs was achieved through secretion of a soluble molecule DKK-1. DKK-1 is one of the most important inhibitors in the WNT signaling pathway. [29] [30] [31] Our results suggest that DKK-1 secreted by MSCs suppresses the WNT signal activity in inhibiting cell proliferation. Therefore, proteins that block WNT signaling cascade, especially the soluble DKK-1, could be used in tumor therapy. It should be noted that the growth rate of K562 was not fully restored to the normal level by RNAi of DKK-1 or by neutralizing antibodies against DKK-1. This may have happened because the inhibition of DKK-1 by the above procedures was incomplete. Alternatively, DKK-1 may not be the only mediator involved in the antitumor mechanism of MSCs. Further experiments are needed to support these hypotheses.
Earlier research has shown that MSCs suppressed T lymphocytes and tumor cells only when they were precursors of matrix cells, 32, 33 which indicates that some intrinsic attributes dictate MSCs to exert this function. Nanog, a unique homeobox transcription factor, is one of the key downstream effectors of LIF, BMP and WNT that support the self-renewal and pluripotency of embryonic stem cells. Elevated levels of Nanog can maintain the self-renewal of mouse embryonic stem cell independent of LIF and enable human embryonic stem cell .01, the number signs were used to mark the statistical significance when comparing with siMock.
Antiproliferative effect of MSCs Y Zhu et al growth independent of feeder cells. 34 We asked whether NANOG, a core transcription factor predominantly expressed in stem cells, is required for the expression of DKK-1. NANOG is observed to bind the promoter of DKK1 and drive its transcription, and knockdown of NANOG by RNAi resulted in a significant downregulation of DKK-1, indicating that NANOG plays a critical role in the expression of DKK-1. On the basis of the aforementioned observations, a model (shown in Supplementary Figure 5 ) is proposed to show the mechanism of MSC inhibition on K562 proliferation. In MSCs, DKK-1 expression is dependent on NANOG regulation. DKK-1 can be secreted by MSCs and bind to the K562 cell surface, leading to the suppression of the canonical WNT signaling pathway, including attenuated b-catenin accumulation. Eventually, K562 cell proliferation is inhibited.
In contrast to the tumor-inhibitory effect of MSCs observed by us and by other groups, several studies have shown that MSCs contribute to the maintenance and progression of cancers. 11, 27, 35 The cancer-promoting effects of MSCs could be attributed to the following reasons: (1) MSCs have the potential to differentiate into vascular endothelial cells, 18 which may innocently participate in the neoplastic process; (2) MSCs have in vivo immunosuppressive properties, which may indirectly protect tumor cells from attack by the immune system. 8 It is known that TGF-b secreted by MSCs is a mediator for MSC suppression on T-lymphocyte proliferation. 9 In humoral microenvironment experiments using Cellmax artificial capillary modules, cells filled in the modules were not allowed to move out, and the immune system of the nude mice was defective. Therefore, the MSCs-mediated inhibitory effect on tumor cells was not interfered with its immunosuppressive effects in our experimental setting. The integrated effects of MSCs on tumor cells probably depend on the immune status of the host, the type of tumor cells, the microenvironments and other unknown factors. For example, in Khakoo's study that used athymic nude mice for tumor formation, MSCs cannot exert their immunosuppressive effects, which otherwise would have favored the growth of tumor cells. 12 In light of all those possible effects MSCs can have on tumor cells, extreme caution should be taken when MSCs are exploited to treat human malignancies. However, those soluble antiproliferative factors secreted by MSCs, similar to DKK-1, could be explored for their potential as therapeutic agents.
